Biomea Fusion, Inc. (BMEA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.65
- As of
Kresmion compiles this page from BMEA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Biomea Fusion, Inc. (BMEA): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-14.
See the full BMEA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BMEA on one page. Preview it with sample data, then open it live with a free account.
Preview the BMEA dossierActive events for BMEA
- mediumEarnings above estimates
Q2-2026: Beat consensus by 47.4%, EPS $-0.12 vs $-0.2282 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 78% of BMEA (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +199% to BMEA (2026Q2)
- high13F: large increase
Point72 Asset Management, L.P. added +90% to BMEA (2026Q2)
- high13F: large increase
RENAISSANCE TECHNOLOGIES LLC added +174% to BMEA (2026Q1)
FREE, NO ACCOUNT
Every event on BMEA, as it fires
You are seeing 5 of 8 events recorded on BMEA since 2026-05-26.
The five above landed across 3 days. The other 3 were recorded on 1 other days. 4 of the 8 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in BMEA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 09077A106 · 2026Q2 | $2.1M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 09077A106 · 2026Q2 | $565K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 09077A106 · 2026Q2 | $66K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 09077A106 · 2026Q2 | $48K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BMEA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
BMEA against its peers
BMEA's return on equity of -209.1% ranks in the 28th percentile of 19 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-03-31.
| Metric | BMEA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 77000 | n/a | 12 |
| Operating margin | n/a | -18478.5% | n/a | 9 |
| Net margin | n/a | -14755.4% | n/a | 9 |
| Return on equity | -209.1% | -110.4% | 28 | 19 |
Peers (24): MREO, IMA, ATNM, ALDX, CNTB, HYPD, ATHE, KLRS, LONA, SGMOQ, SER, GANX, RNTX, ANVS, HOWL, GRDX, INMB, ELTX, ELOX, ESLA, INKT, GRCE, VERU, BOLD. Left out: HSTC (period gap). Fiscal periods ending between 2025-06-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (BMEA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow BMEA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to BMEA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.